Georg Ebersbach (Movement Disorders Clinic, Beelitz-Heilstaetten, Beelitz, Germany) kindly took the time to talk us through the findings of his presentation entitled: Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II.
ClinicalTrials.gov identifiers for the two large multinational trials included in this post-hoc analysis, that previously demonstrated efficacy and safety of opicapone for end-of-dose motor fluctuations in Parkinson’s disease: NCT01568073 and NCT01227655, respectively.
1. What impact do motor fluctuations have on patients with Parkinson’s disease (PD)? (0:06)
2. Could you give us a brief overview of the main findings of the BIPARK-I and II studies supporting the use of opicapone in PD? (0:47)
3. What was the rationale for the post-hoc analysis you presented? (1:54)
4. What were the findings of this analysis? (2:24)
5. What are the implications of these findings in terms of the optimum use of opicapone in routine clinical practice? (3:35)
Disclosures: Prof. Ebersbach reports receiving honoraria for lectures and advisory board activities from BIAL, the manufacturer of opicapone.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Angelo Antonini, EAN 2023: Highlights in Parkinson’s disease
touchNEUROLOGY editorial board member Prof. Angelo Antonini (Padua University Hospital, Italy) provides an overview of his top three most important updates and hot topics from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of Parkinson’s disease. He particularly focusses on new insights in early detection of the disease before motor symptoms […]
Highlights from EAN 2023!
Veronica Clark, Parkinson’s Europe: Presidential Update, and the Parkinson’s Manifesto for Europe
The European Parkinson’s Disease Association (EPDA) recently changed its name to Parkinson’s Europe. They are the only European Parkinson’s umbrella organisation and have been working with the global Parkinson’s community for nearly 30 years. As a leading voice for Parkinson’s in Europe, they provide trusted information; advance and share good practices; raise awareness and improve […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!